Antibody · 고형암 (전체) · HER2

17개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved17 programs
AntibodyCurated CoreFDARocheApproved

trastuzumab (Herceptin, Ogivri, Herzuma)

HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma · HER2

#HER2#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1100Status Approved
AntibodyCurated CoreFDABeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved
AntibodyCurated CoreFDAJazz PharmaceuticalsApproved

zanidatamab (Ziihera, ZW25, zanidatamab-hrii)

First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract can… · HER2 (biparatopic)

#HER2biparatopic#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 35Status Approved
AntibodyCurated CoreFDAAstellasApproved

zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab)

CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma · CLDN18.2 (claudin-18.2)

#CLDN182claudin-182#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 26Status Approved
AntibodyCurated CoreBristol Myers SquibbPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 470Status Active
AntibodyLimited DatastaleInnoventPhase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 152Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab (Camrelizumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 127Status Recruiting
AntibodyLimited DatastaleAkesoPhase 2

cadonilimab (cadonilimab)

Metastatic HER2 Positive Gastroesophageal Junction Cancer · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 85Status Recruiting
AntibodyCurated CorestaleAkesoPhase 2

Ivonescimab (Ivonescimab)

Advanced Microsatellite Stable Colorectal Carcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma · HER2

#HER2#Antibody#Phase2#BioJungboMoa-pick#Popular+5
Trials 78Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, HER2, pyrotinib + pertuzumab/trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#SalivaryGlandCarcinoma+2
Trials 30Status Recruiting
AntibodyLimited DatastaleMargaret Gatti-MaysPhase 2

Naxitamab (Naxitamab)

Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AnatomicStageIVBreastCancerAJCCv+2
Trials 2Status Recruiting
AntibodyLimited DatastaleTianjin Medical University Canc…Preclinical

Enituzumab injection+Abesili tablets+Anastrozole tablets (Enituzumab injection+Abesili tablets+Anastrozole tablets)

Advanced HR+ HER2 Negative Breast Carcinoma · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#AdvancedHR+HER2NegativeBreastCar+1
Trials 1Status Active
AntibodyLimited DatastaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#Melanoma+2
Trials 1Status Active
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®23104 (XmAb®23104)

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting